South Korea
· Delayed Price · Currency is KRW GeneOne Life Science Statistics
Total Valuation
GeneOne Life Science has a market cap or net worth of KRW 159.26 billion. The enterprise value is 178.95 billion.
| Market Cap | 159.26B |
| Enterprise Value | 178.95B |
Important Dates
The next estimated earnings date is Friday, March 14, 2025.
| Earnings Date | Mar 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GeneOne Life Science has 79.83 million shares outstanding. The number of shares has increased by 1.93% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 79.83M |
| Shares Change (YoY) | +1.93% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | 11.61% |
| Owned by Institutions (%) | 4.76% |
| Float | 70.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.15 |
| PB Ratio | 1.80 |
| P/TBV Ratio | 1.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.46 |
| EV / Sales | 4.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.42 |
Financial Position
The company has a current ratio of 0.98, with a Debt / Equity ratio of 0.26.
| Current Ratio | 0.98 |
| Quick Ratio | 0.35 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.97 |
| Interest Coverage | -28.21 |
Financial Efficiency
Return on equity (ROE) is -58.95% and return on invested capital (ROIC) is -19.90%.
| Return on Equity (ROE) | -58.95% |
| Return on Assets (ROA) | -16.86% |
| Return on Capital (ROIC) | -19.90% |
| Revenue Per Employee | 825.42M |
| Profits Per Employee | -1.58B |
| Employee Count | 46 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 2.90 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.51% in the last 52 weeks. The beta is -2.10, so GeneOne Life Science's price volatility has been lower than the market average.
| Beta (5Y) | -2.10 |
| 52-Week Price Change | -24.51% |
| 50-Day Moving Average | 2,222.66 |
| 200-Day Moving Average | 2,450.67 |
| Relative Strength Index (RSI) | 38.02 |
| Average Volume (20 Days) | 218,611 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GeneOne Life Science had revenue of KRW 37.97 billion and -72.69 billion in losses. Loss per share was -919.97.
| Revenue | 37.97B |
| Gross Profit | -8.02B |
| Operating Income | -44.45B |
| Pretax Income | -72.56B |
| Net Income | -72.69B |
| EBITDA | -26.92B |
| EBIT | -44.45B |
| Loss Per Share | -919.97 |
Balance Sheet
The company has 3.63 billion in cash and 23.32 billion in debt, giving a net cash position of -19.69 billion or -246.68 per share.
| Cash & Cash Equivalents | 3.63B |
| Total Debt | 23.32B |
| Net Cash | -19.69B |
| Net Cash Per Share | -246.68 |
| Equity (Book Value) | 88.28B |
| Book Value Per Share | 1,105.85 |
| Working Capital | -670.92M |
Cash Flow
In the last 12 months, operating cash flow was -19.53 billion and capital expenditures -4.59 billion, giving a free cash flow of -24.12 billion.
| Operating Cash Flow | -19.53B |
| Capital Expenditures | -4.59B |
| Free Cash Flow | -24.12B |
| FCF Per Share | -302.15 |
Margins
Gross margin is -21.12%, with operating and profit margins of -117.07% and -191.44%.
| Gross Margin | -21.12% |
| Operating Margin | -117.07% |
| Pretax Margin | -191.09% |
| Profit Margin | -191.44% |
| EBITDA Margin | -70.89% |
| EBIT Margin | -117.07% |
| FCF Margin | n/a |
Dividends & Yields
GeneOne Life Science does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.93% |
| Shareholder Yield | -1.93% |
| Earnings Yield | -46.11% |
| FCF Yield | -15.15% |
Stock Splits
The last stock split was on December 3, 2021. It was a forward split with a ratio of 1.5.
| Last Split Date | Dec 3, 2021 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
GeneOne Life Science has an Altman Z-Score of -0.79. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.79 |
| Piotroski F-Score | n/a |